West Pharmaceutical Services, Inc. (WST)

From the record

West Pharmaceutical Services, Inc.'s filings since 2017 show 2 warning events: a material cybersecurity incident (8-K item 1.05, 2 times, the latest 2026-05-20) (its current reports).

From the record

West Pharmaceutical Services, Inc.'s 8 filed years say what it did: revenue went from $1.7 billion in fiscal 2018 to $3.1 billion in fiscal 2025, up 8.7% a year; it rose in 6 of 7 years; the deepest fall was 2% from fiscal 2023 to fiscal 2024; net income was positive in 8 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, West Pharmaceutical Services, Inc.'s diluted share count shrank about 1.4% a year, and dividends and buybacks returned about 60% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 8 sales (3 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-02 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, West Pharmaceutical Services, Inc. earned about 16 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 26 cents per dollar of everything the company owns. Leverage: it owed about 26 cents per dollar of assets, and net share issuance: its share count shrank 1.4% over the year (the filed statements).

From the record

West Pharmaceutical Services, Inc.'s standing among 109 graded names in its industry family: revenue of $3.1 billion in fiscal 2025 ranks in the top 10% by size; a net margin of 16.1% ranks in the top 11%; revenue growth of 2.1% a year over the last 3 filed years ranks in the bottom 25% (its annual reports).

From the record

West Pharmaceutical Services, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lagarde, Michel (President and CEO, as filed), filing under that title since 2026-09-10, 2 months (bottom 3% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 6.5 years (top 29%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (bottom 44%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

West Pharmaceutical Services, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $791 million against debt of $203 million leaves 13.8% of its assets as net cash, top 44% of its family; cash from operations less capital spending is 15.3% of revenue (top 15%); a gross margin of 35.9% (bottom 16%); research spending of 2.4% of revenue (bottom 11%) (its annual report).

From the record

West Pharmaceutical Services, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.1% a year over the last three filed years against 8.7% over all 8, slowing (bottom 32% of its family); the newest year grew 6.3% (bottom 31%); research spending grew 8.3% a year (top 44%); capital spending grew 0.2% a year (top 47%) (its annual reports). West Pharmaceutical Services, Inc. reported 2 lines of business in fiscal 2025: Proprietary Products at $2.5 billion (81%), Contract Manufactured Products at $582 million (19%); 2 of 2 grew against the year before (its annual report).

From the record

West Pharmaceutical Services, Inc.'s newest year against its own record: revenue of $3.1 billion in fiscal 2025 came in 6.1% above the $2.9 billion its prior three years' pace pointed to (top 20% of its family); net income of $494 million against a prior three-year average of $557 million (bottom 34%); a net margin of 16.1% against 19.1% before (bottom 19%) (its annual reports).